WHO Sounds Alert Over Critical Scarcity of Obesity Medications
Under 10% of patients eligible to benefit from GLP-1 drugs such as Wegovy have access to them, caution the World Health Organization as it issues its initial guidance on the drugs.
With in excess of 1,000,000,000 people worldwide now classified as obese, it is advocating for broader and more equitable availability to GLP-1 medication.
According to projections, more than two billion will be living with obesity by 2030 if no action is taken.
"The latest guidance recognises that obesity is a lifelong illness that can be treated with holistic and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant barriers to broad availability to the jabs that can help people shift considerable body mass, explains the organization.
Skinny Jab Shortage
Even in the current best projected case, the production of these medications might only reach approximately 100 million people – less than 10% of the global need, per the health organization.
The recommendation encourages countries and companies to expand availability, by strategies including patent sharing.
Exclusive production rights on semaglutide – the primary ingredient of a leading brand – is set to lapse in several nations in 2026.
How Weight-Loss Drugs Function
These medications mimick a biological compound to slow digestion, suppress the appetite and boost the sense of being full so people eat less.
Individuals typically begin shedding pounds within a few weeks of beginning the regular doses.
Studies points to users may put most of the weight back on within a year of stopping the treatment, as their normal appetite resume.
To be carrying excess weight elevates your risk for developing health problems, like type 2 diabetes, heart disease, brain attack, and some malignancies.
Obesity concerns individuals in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, according to the WHO.
